OmegaQuant Analytics, the producer of The Omega-3 Index, has launched a new Prenatal DHA Test developed for expecting mothers to monitor their omega-3 DHA level.
Photo © iStockphoto.com/Rinelle
OmegaQuant Analytics (Siox Falls, SD), the producer of The Omega-3 Index, has launched a new Prenatal DHA Test developed for expecting mothers to monitor their omega-3 DHA level. This is an important measure for pregnant women because there is evidence that deficiency in omega-3 long chain polyunsaturated fatty acids can increase the risk of preterm birth.
A meta-analysis1 conducted by Cochrane of 70 randomized control trials, involving 19,927 women, found that preterm birth (<37 weeks of gestation) and very preterm birth (<34 weeks of gestation) was reduced by 11% and 42% respectively when women took omega-3 supplements, and determined that it is an effective strategy for reducing the risk of preterm births. Another recent study2 found that the risk of early preterm birth (<34 weeks of gestation) was 10 times higher in women in the lowest quintile, with an EPA and DHA omega-3 concentration of less than 1.6% of total plasma fatty acids.
Using this data, and converting the EPA and DHA plasma levels to red blood cell DHA levels, OmegaQuant determined that pregnant women should strive to have DHA levels of at least 5% (meaning that 5% of her red blood cell fatty acids are DHA). “In a study3 we published in December, we estimated that 70% of women of childbearing age in the US are below the 5% DHA cutoff. There are no known risks to having a DHA level that is too high in pregnancy, except for the potential of carrying a baby past 40 weeks. Still, the longer a baby can stay in the womb, the lower the chances are for complications,” said Kristina Harris Jackson, PhD, RD, a research associate at OmegaQuant Analytics, in a press release. “It’s hard to think of a more important biomarker than prenatal DHA levels that can be safely and easily modified and has such potentially consequential outcomes.”
1. Middleton P. et al. “Omega-3 fatty acid addition during pregnancy.” Cochrane Database of Systematic Reviews, vol 11 (November 2018)
2. Olsen S.F. et al. “Plasma concentrations of long chain omega-3 fatty acids in early and mid-pregnancy and risk of early preterm birth.” EBioMedicine, vol 35 (September 2018): 325-333
3. Jackson K.H et al. “A prenatal DHA test to help identify women at increased risk for early preterm birth: a proposal.” Nutrients, vol 10, no. 12 (December 2018)
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
GC Rieber VivoMega uses AI platform from Intelecy to boost efficiency, quality, and sustainability
August 26th 2024According to the company’s announcement, the AI platform is able to identify real-time deviations or anomalies in GC Rieber VivoMega’s processing facilities and report them via a cloud-based, comprehensive, centralized system.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.